Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -278.89% is 24% below its 1-year average of -224.99%, around the middle of its 1-year range (-632.98%–-56.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.38% above its 12-month average of -288.64%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -278.89%.
RETURN ON EQUITY (ROE)
-278.89%
RETURN ON EQUITY (ROE) AVG TTM
-288.64%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+3.38%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-563.86%
vs the sector median at left
eXoZymes, Inc.
Market Cap
$51.23M
Return on Equity (ROE)
-278.89%
TTM Avg
-288.64%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.19M
Return on Equity (ROE)
-57.10%
TTM Avg
-36.66%
3Y Avg
-227.16%
5Y Avg
-314.45%
Market Cap
$51.12M
Return on Equity (ROE)
-52.72%
TTM Avg
-32.48%
3Y Avg
-92.81%
5Y Avg
-85.98%
Market Cap
$51.88M
Return on Equity (ROE)
-36.94%
TTM Avg
-31.55%
3Y Avg
-37.51%
5Y Avg
-20.44%
Market Cap
$51.99M
Return on Equity (ROE)
N/A
TTM Avg
31.64%
3Y Avg
119.26%
5Y Avg
-26.51%
Market Cap
$50.28M
Return on Equity (ROE)
N/A
TTM Avg
-24.59%
3Y Avg
-14.57%
5Y Avg
93.61%
Market Cap
$50.27M
Return on Equity (ROE)
-708.48%
TTM Avg
156.13%
3Y Avg
510.26%
5Y Avg
342.91%
Market Cap
$52.60M
Return on Equity (ROE)
-27.93%
TTM Avg
-11.97%
3Y Avg
0.83%
5Y Avg
3.58%
Market Cap
$49.71M
Return on Equity (ROE)
-90.44%
TTM Avg
-163.19%
3Y Avg
-112.62%
5Y Avg
-86.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| eXoZymes, Inc. (EXOZ) | $51.23M | -278.89% | -288.64% | N/A | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | -57.10% | -36.66% | -227.16% | -314.45% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | -52.72% | -32.48% | -92.81% | -85.98% |
| ImageneBio Inc (IMA)vs › | $51.88M | -36.94% | -31.55% | -37.51% | -20.44% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A | 31.64% | 119.26% | -26.51% |
| biote Corp. (BTMD)vs › | $50.28M | N/A | -24.59% | -14.57% | 93.61% |
| Envoy Medical, Inc. (COCH)vs › | $50.27M | -708.48% | 156.13% | 510.26% | 342.91% |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | -27.93% | -11.97% | 0.83% | 3.58% |
| INmune Bio, Inc. (INMB)vs › | $49.71M | -90.44% | -163.19% | -112.62% | -86.58% |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | N/A | 171.70% | 384.85% | 251.73% |
ROE
-278.9%
ROA
-127.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -278.89% |
| 2026-03-31 | -632.98% |
| 2025-12-31 | -269.59% |
| 2025-09-30 | -155.17% |
| 2025-06-30 | -106.54% |
| 2025-03-31 | -75.54% |
| 2024-12-31 | -56.25% |
